Table 3.
Effectiveness of subsequent chemotherapy
| Overall | Paclitaxel ± cetuximab |
S-1 therapy | Platinum-based therapy | |
|---|---|---|---|---|
| Total patients | 95 (100.0) | 52 (54.7) | 13 (13.7) | 12 (12.6) |
|
Evaluable patients, n (%) |
70 (73.7) | 42 (44.2) | 6 (6.3) | 10 (10.5) |
| BOR | ||||
| Complete response | 4 (5.7) | 3 (7.1) | 1 (16.7) | 0 (0.0) |
| Partial response | 19 (27.1) | 12 (28.6) | 1 (16.7) | 4 (40.0) |
| Stable disease | 17 (24.3) | 13 (31.0) | 0 (0.0) | 2 (20.0) |
| Progressive disease | 30 (42.9) | 14 (33.3) | 4 (66.7) | 4 (40.0) |
| ORR | 23 (32.9) 95% CI 22.1–45.1 | 15 (35.7) 95% CI 21.6–52.0 | 2 (33.3) 95% CI 4.3–77.7 | 4 (40.0) 95% CI 12.2–73.8 |
| DCR | 40 (57.1) 95% CI 44.7–68.9 | 28 (66.7) 95% CI 50.5–80.4 | 2 (33.3) 95% CI 4.3–77.7 | 6 (60.0) 95% CI 26.2–87.8 |
Data are n (%)
Response rates were calculated in evaluable patients
BOR best overall response, CI confidence interval, DCR disease control rate, ORR objective response rate